menu
    • menu

    Company profile for Luxa Biotechnology

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Luxa Biotechnology is advancing a pioneering adult RPE stem cell (RPESC) therapy for dry AMD in its clinical-stage development. The exclusive RPESC-derived RPE stem cell product originated and is licensed from the Neural Stem Cell Institute (NSCI). Luxa operates as a collaboration between NSCI in New York, USA, and Y2 Solution in Seoul, Korea. Currently, Luxa is conducting clinical trials to evaluate the safety and effectivene...
    Luxa Biotechnology is advancing a pioneering adult RPE stem cell (RPESC) therapy for dry AMD in its clinical-stage development. The exclusive RPESC-derived RPE stem cell product originated and is licensed from the Neural Stem Cell Institute (NSCI). Luxa operates as a collaboration between NSCI in New York, USA, and Y2 Solution in Seoul, Korea. Currently, Luxa is conducting clinical trials to evaluate the safety and effectiveness of RPESC-RPE-4W, a distinctive RPE progenitor stage cell product, as a prospective treatment for dry AMD.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Luxa BiotechnologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Suite 435, Fort Lee, NJ 07024
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.luxabiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/luxabiotechnology/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Luxa Biotech Publishes Positive Results for First Human Trial
    Luxa Biotech Publishes Positive Results for First Human Trial

    17 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-17/luxa-biotechnology-announces-publication-in-cell-stem-cell-describing-positive-clinical-results-for

    PHARMAWEB
    17 Sep 2025
    Share Share
    Luxa to Present RPESC-RPE-4W Therapy Data at 2025 ARVO Meeting
    Luxa to Present RPESC-RPE-4W Therapy Data at 2025 ARVO Meeting

    29 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250429713414/en/Luxa-to-Present-Phase-12a-Clinical-and-Preclinical-Data-on-RPESC-RPE-4W-Therapy-for-Dry-AMD-at-2025-ARVO-Annual-Meeting

    BUSINESSWIRE
    29 Apr 2025
    Share Share
    Luxa Biotechnology Presents Clinical Data at Wills Eye Conference
    Luxa Biotechnology Presents Clinical Data at Wills Eye Conference

    06 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250306998366/en

    BUSINESSWIRE
    06 Mar 2025
    Share Share
    Luxa Biotech’s RPESC-RPE-4W Gets FDA RMAT For Dry AMD Treatment
    Luxa Biotech’s RPESC-RPE-4W Gets FDA RMAT For Dry AMD Treatment

    18 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250218104018/en

    BUSINESSWIRE
    18 Feb 2025
    Share Share
    Luxa Biotechnology Appoints Keith E. Dionne As CEO
    Luxa Biotechnology Appoints Keith E. Dionne As CEO

    01 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241001316266/en

    BUSINESSWIRE
    01 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search